UBS Group
SMMT icon

UBS Group’s Summit Therapeutics SMMT Stock Holding History

UBS Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
72,400
+52,400
+262% +$929K ﹤0.01% 5687
2026
Q1 		$379K Buy
+20,000
New +$323K ﹤0.01% 6266
2025
Q4 		– Sell
-85,000
Closed -$1.76M – 11102
2025
Q3 		$1.76M Buy
+85,000
New +$2.06M ﹤0.01% 5080

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's SMMT Position: Q2 2026 in Review

UBS Group increased its Summit Therapeutics (SMMT) stake by 42% in Q2 2026, buying an estimated $27.5M and bringing the position to 5,233,798 shares worth $76.3M. The position accounts for 0.01% of the portfolio, ranked #1336.

UBS Group first reported a position in SMMT in Q2 2015 and has held it in 37 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • UBS Group held 5,233,798 shares of Summit Therapeutics worth $76.3M as of Q2 2026.
  • UBS Group bought 1,553,483 Summit Therapeutics shares in Q2 2026, an estimated $27.5M.
  • Summit Therapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1336 holding.
  • UBS Group first reported a position in Summit Therapeutics in Q2 2015 and has held it in 37 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.